[18F]SYN2(一种PET心脏灌注示踪剂)在健康受试者中的生物分布、安全性特征与辐射剂量学研究
首次人体I期临床研究在10名健康受试者中评估了心脏PET心肌灌注显像示踪剂[18F]SYN2的安全性、辐射剂量学和生物分布。受试者接受静脉注射后行全身序列PET显像,未见药物相关不良事件,示踪剂耐受良好,全身有效辐射剂量为0.0195 mSv/MBq。示踪剂被心肌壁快速摄取并迅速从血浆清除,注射后数分钟内即可获得良好图像质量,研究者认为其是有前景的临床PET心肌灌注显像药物并值得进一步临床研究。
要点
- 10名健康受试者(8女2男)完成全部研究程序,平均年龄38.1±8.8岁,平均体重指数22.7±3.0 kg/m2。
- 平均给药放射性活度为258 MBq(范围246-272 MBq),未见药物相关不良事件,所有受试者耐受良好。
- [18F]SYN2全身有效辐射剂量为0.0195 mSv/MBq,心肌壁快速摄取、血浆快速清除,注射后数分钟内图像质量良好。
核心结论
- 基于[18F]SYN2的安全性特征、辐射剂量学和生物分布,研究者认为其似乎是临床PET心肌灌注显像的有前景药物,并值得进一步临床研究。
研究设计与样本
- 首次人体I期临床研究,在健康受试者中评估[18F]SYN2(18F标记吖啶衍生物)的安全性、辐射剂量学和生物分布。
- 健康志愿者接受[18F]SYN2静脉给药后行PET显像,并在4小时内进行全身序列显像;血液和尿液样本采集至240分钟。
- 安全性随访在给药后2天、5天和14天进行;共10名受试者(8名女性、2名男性)完成全部研究程序。
主要发现
- 受试者平均年龄38.1±8.8岁,平均体重指数22.7±3.0 kg/m2。
- 平均给药放射性活度为258 MBq(范围246-272 MBq)。
- 未见药物相关不良事件,示踪剂在所有受试者中耐受良好。
- [18F]SYN2的平均全身有效辐射剂量为0.0195 mSv/MBq。
- 示踪剂被心肌壁快速摄取并迅速从血浆清除,注射后数分钟内即可获得良好图像质量。
局限性
- 原文结论指出[18F]SYN2 appears to be a promising agent并warrant further clinical studies。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A first-in-human phase I clinical study aimed to assess the safety profile, radiation dosimetry, and biodistribution of a potential cardiac PET myocardial perfusion imaging tracer, [18F]SYN2 (18F-labeled acridine derivative), in healthy subjects. Methods: [18F]SYN2 intravenous administration with PET imaging was performed on healthy volunteers, and sequential whole-body imaging was performed over 4 h. Blood and urine samples were collected for up to 240 min. Safety follow-up visits took place at 2, 5, and 14 d after the administration. Results: Ten subjects (8 women and 2 men) completed all study procedures. The mean age was 38.1 ± 8.8 y, and the mean body mass index was 22.7 ± 3.0 kg/m2 The mean administered dose of radioactivity was 258 MBq (range, 246-272 MBq). There were no drug-related adverse events, and the tracer was well tolerated in all subjects. The mean whole-body effective radiation dose for [18F]SYN2 was 0.0195 mSv/MBq. The tracer was rapidly taken up by the myocardial wall and cleared from plasma, leading to good image quality within minutes of tracer injection. Conclusion: On the basis of the safety profile, radiation dosimetry, and biodistribution of [18F]SYN2, it appears to be a promising agent for clinical PET myocardial perfusion imaging and to warrant further clinical studies.
引用
- Knuuti J, Kobylecka M, Krajewski S, et al. Biodistribution, Safety Profile, and Radiation Dosimetry of [18F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects. J Nucl Med. 2025. PMID: 40049745. doi:10.2967/jnumed.124.268872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。